Lenakast 25mg Capsule (Lenalidomide): Comprehensive Clinical Profile & Global Supply Guide Lenakast 25mg Capsule is a high-potency immunomodulatory drug (IMiD) containing the active pharmaceutical ingredient Lenalidomide. It is a cornerstone therapy in modern hematology and oncology, specifically designed to treat various plasma cell dyscrasias and complex blood cancers. As a structural analogue of thalidomide, Lenakast 25mg offers a targeted approach to inhibiting tumor growth while stimulating the body's natural immune response. Manufactured by Aprazer Healthcare, Lenakast is a trusted choice for oncology centers worldwide. Therapeutic Indications and Clinical Usage Lenakast 25mg is extensively utilized across global oncology protocols for: Multiple Myeloma (MM): Used in combination with dexamethasone for patients with newly diagnosed multiple myeloma or those who have received at least one prior therapy. It is also a primary choice for maintenance therapy following autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after two prior therapies, providing a vital line of defense. Follicular Lymphoma & Marginal Zone Lymphoma: Employed in combination with rituximab for previously treated patients to achieve better remission rates and progression-free survival. The Mechanism: How Lenakast 25mg Works Lenakast exerts its anti-cancer effects through a sophisticated multi-pathway mechanism: Immune Modulation: It enhances T-cell and Natural Killer (NK) cell-mediated immunity, significantly increasing the body's innate ability to identify and destroy malignant cells. Anti-Angiogenesis: It blocks the secretion of vascular endothelial growth factor (VEGF), effectively preventing the formation of new blood vessels that tumors need to survive and spread. Direct Cytotoxicity: It induces cell cycle arrest and apoptosis (programmed cell death) specifically in hematopoietic tumor cells. Anti-Inflammatory Action: It inhibits the production of pro-inflammatory cytokines such as TNF-α and various Interleukins (IL-1, IL-6, and IL-12). Dosage and Administration Guidelines Cycle-Based Dosing: Typically administered in 28-day cycles. For multiple myeloma, the standard dose is 25 mg taken orally once daily on Days 1–21, followed by a 7-day rest period. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Timing: Can be taken with or without food, but should be taken at the same time each day to maintain steady therapeutic levels. Renal Monitoring: Since the drug is primarily excreted by the kidneys, dosage adjustments are strictly managed for patients with impaired renal function. Safety Profile and Side Effect Management Clinical management of Lenakast 25mg requires vigilant professional oversight: 1. Hematological Support The most frequent side effects are neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular blood counts (CBC) are mandatory to monitor for infection or bleeding risks. If counts drop too low, a dose reduction or temporary pause is usually implemented. 2. Thromboembolism Prophylaxis There is a significantly increased risk of blood clots (DVT or Pulmonary Embolism). Patients are almost always prescribed prophylactic anticoagulants (like aspirin or heparin) alongside Lenakast. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are typically managed with supportive care, adequate hydration, and symptomatic medication. Storage and Handling Temperature: Store at room temperature, 20°C to 25°C (68°F to 77°F). Security: Keep in the original blister pack to protect from light and moisture. Safety: Caregivers should wear gloves if handling the capsules directly to avoid accidental skin exposure to the active powder. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ WHO-GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383
Washington, USA
08048034998
+919405476170
Chat with us
Chat with us
